Logo

Takeda’s Hyqvia Receives the US FDA Approval as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Share this
Takeda

Takeda’s Hyqvia Receives the US FDA Approval as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Shots:

  • The company’s Hyqvia has been approved by the US FDA as maintenance therapy for adults with CIDP to prevent relapse of neuromuscular disability and impairment
  • The approval was supported by the results from P-III (ADVANCE-CIDP 1) study investigating Hyqvia’s safety, efficacy and tolerability as maintenance therapy in adults with CIDP as well as the P-III (ADVANCE-CIDP 3) trial that enrolled patients who completed (ADVANCE-CIDP 1)
  • The results from the (ADVANCE-CIDP 1) study in 122 evaluable CIDP patients on stable IVIG therapy revealed a difference of -18.3% in relapse rates b/w the Hyqvia (14.0%) vs PBO (32.3%) indicating Hyqvia's superiority in preventing CIDP relapse

Ref: Takeda Image: Takeda

Related News:- Takeda Presents P-III Trial (ADVANCE-CIDP 1) Results of Hyqvia for Chronic Inflammatory Demyelinating Polyneuropathy at PNS 2023, Published in the JPNS

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions